GLS and hematologic disorder: Selective glutaminase inhibitors, such as CB-839 (N-(5-(4-(6-((2-(3-(Trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-2-pyridineacetamide) have been the subject of clinical trials in solid tumors and hematological malignancies (ClinicalTrials.gov Identifier: NCT02071862, ClinicalTrials.gov Identifier: NCT02071888, and ClinicalTrials.gov Identifier: NCT02071927).